
ENOVIS CORP
ENOVNYSETrading Snapshot
- Day Range
- $24.40 β $25.02
- 52-Week Range
- $19.14 β $34.28
- Volume
- $6.13B
- Avg Volume
- $5.84B
- Shares Outstanding
- 57.6M
- Next Earnings
- Oct 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.25B
- Last Q Revenue
- $583M
- P/E Ratio
- -1.3
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-19.13
- Dividend Yield
- 0.00%
Why Investors Own ENOV
- βHigh-growth profile β revenue up +51.8% YoY with expanding US Equity exposure.
- βHealthy economics β 57% gross margin and 7% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ENOVIS CORP
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionalsβincluding orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainersβwho treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
Wells Fargo Maintains Overweight on Enovis, Lowers Price Target to $39
Wells Fargo analyst Larry Biegelsen maintains Enovis (NYSE:ENOV) with a Overweight and lowers the price target from $40 to $39.

Enovis Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Enovis Corporation in conjunction with their 2026 Q2 earnings call.

Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript
Enovis Corporation (ENOV) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsKyle Rose - Vice President of Investor RelationsDamien...
BTIG Maintains Buy on Enovis, Raises Price Target to $40
BTIG analyst Ryan Zimmerman maintains Enovis (NYSE:ENOV) with a Buy and raises the price target from $39 to $40.
Enovis Q2 Adj. EPS $0.90 Beats $0.85 Estimate, Sales $582.782M Beat $582.542M Estimate
Enovis (NYSE:ENOV) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.85 by 5.88 percent. This is a 13.92 percent increase over earnings of $0.79 per share from the same
Enovis Affirms FY2026 Adj EPS Guidance of $3.52-$3.73 vs $3.65 Est; Affirms FY2026 Sales Guidance of $2.310B-$2.370B vs $2.345B Est
Enovis (NYSE:ENOV) affirms FY2026 Adj EPS guidance from $3.52-$3.73 to $3.52-$3.73 vs $3.65 analyst estimate. Affirms FY2026 sales outlook from $2.310 billion-$2.370 billion to $2.310 billion-$2.370 billion vs $2.345